Nuveen LLC Takes $10.01 Million Position in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Nuveen LLC has invested approximately $10.01 million in Aurinia Pharmaceuticals by purchasing 1,245,549 shares, representing a 0.91% ownership stake.
• Insider transactions show that Director Kevin Tang acquired 1,000,000 shares for about $10.12 each, increasing his ownership to over 11 million shares valued at roughly $111.6 million.
• Aurinia Pharmaceuticals' stock performance includes a market cap of $1.62 billion and a recent earnings report indicates a revenue of $70.01 million for the quarter, surpassing analyst estimates.

Nuveen LLC acquired a new position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,245,549 shares of the biotechnology company's stock, valued at approximately $10,014,000. Nuveen LLC owned about 0.91% of Aurinia Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Deutsche Bank AG lifted its stake in shares of Aurinia Pharmaceuticals by 54.8% in the fourth quarter. Deutsche Bank AG now owns 142,869 shares of the biotechnology company's stock worth $1,283,000 after buying an additional 50,575 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Aurinia Pharmaceuticals by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,314 shares of the biotechnology company's stock worth $685,000 after buying an additional 2,887 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the first quarter worth $86,000. GAMMA Investing LLC raised its stake in Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 1,744 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Aurinia Pharmaceuticals by 19.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,098 shares of the biotechnology company's stock valued at $468,000 after purchasing an additional 8,350 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Aurinia Pharmaceuticals news, Director Kevin Tang acquired 1,000,000 shares of the company's stock in a transaction dated Friday, August 1st. The stock was bought at an average price of $10.12 per share, for a total transaction of $10,120,000.00. Following the purchase, the director owned 11,029,500 shares in the company, valued at $111,618,540. This represents a 9.97% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders have acquired 1,300,000 shares of company stock valued at $13,590,000. Corporate insiders own 12.20% of the company's stock.

Analysts Set New Price Targets

AUPH has been the subject of several research analyst reports. Royal Bank Of Canada upped their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. HC Wainwright reiterated a "buy" rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $12.00.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH traded down $0.03 during trading hours on Thursday, hitting $12.08. 1,081,028 shares of the company traded hands, compared to its average volume of 2,842,036. Aurinia Pharmaceuticals Inc has a twelve month low of $6.42 and a twelve month high of $12.53. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of 28.09 and a beta of 1.23. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The firm has a 50-day moving average of $9.81 and a 200 day moving average of $8.64.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.